

Meike de Wit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8066948/publications.pdf>

Version: 2024-02-01

41
papers

1,610
citations

304743

22
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

2729
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948. | 3.7 | 209 |
| 2 | Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications, 2021, 12, 5060. | 12.8 | 161 |
| 3 | <i>TPX2</i> and <i>AURKA</i> promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut, 2012, 61, 1568-1575. | 12.1 | 118 |
| 4 | The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin. American Journal of Clinical Pathology, 2014, 141, 630-638. | 0.7 | 116 |
| 5 | The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2242-2258. | 2.3 | 95 |
| 6 | Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut, 2012, 61, 855-864. | 12.1 | 82 |
| 7 | Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. Journal of Proteomics, 2014, 99, 26-39. | 2.4 | 81 |
| 8 | Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clinical Biochemistry, 2013, 46, 466-479. | 1.9 | 80 |
| 9 | Whole gel processing procedure for GeLC-MS/MS based proteomics. Proteome Science, 2013, 11, 17. | 1.7 | 75 |
| 10 | Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumor Biology, 2010, 31, 89-96. | 1.8 | 74 |
| 11 | Subnuclear Proteomics in Colorectal Cancer. Molecular and Cellular Proteomics, 2010, 9, 988-1005. | 3.8 | 61 |
| 12 | Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer. Clinical Cancer Research, 2012, 18, 2613-2624. | 7.0 | 46 |
| 13 | Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. British Journal of Cancer, 2013, 109, 1636-1647. | 6.4 | 41 |
| 14 | <i>BCL2L1</i> has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain. Journal of Pathology, 2012, 226, 442-450. | 4.5 | 39 |
| 15 | Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening. Annals of Internal Medicine, 2017, 167, 855. | 3.9 | 39 |
| 16 | MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget, 2015, 6, 26278-26290. | 1.8 | 39 |
| 17 | Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression. Journal of Pathology, 2020, 250, 288-298. | 4.5 | 33 |
| 18 | Lumican and Versican Are Associated with Good Outcome in Stage II and III Colon Cancer. Annals of Surgical Oncology, 2013, 20, 348-359. | 1.5 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. <i>International Journal of Cancer</i> , 2020, 146, 1979-1992. | 5.1 | 32 |
| 20 | Peptide-mediated <i>miniprep</i> ™ isolation of extracellular vesicles is suitable for high-throughput proteomics. <i>EuPA Open Proteomics</i> , 2016, 11, 11-15. | 2.5 | 28 |
| 21 | Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression. <i>PLoS ONE</i> , 2017, 12, e0174768. | 2.5 | 27 |
| 22 | CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 293-300. | 4.4 | 25 |
| 23 | Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening. <i>Annals of Internal Medicine</i> , 2021, 174, 1224-1231. | 3.9 | 16 |
| 24 | Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas. <i>Cancer Prevention Research</i> , 2018, 11, 403-412. | 1.5 | 15 |
| 25 | Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer. <i>European Journal of Cancer</i> , 2021, 144, 91-100. | 2.8 | 14 |
| 26 | Loss of enteric neuronal <i>Ndr4</i> promotes colorectal cancer via increased release of Nid1 and Fbln2. <i>EMBO Reports</i> , 2021, 22, e51913. | 4.5 | 14 |
| 27 | Proteomics of differential extraction fractions enriched for chromatin-binding proteins from colon adenoma and carcinoma tissues. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1034-1043. | 2.3 | 8 |
| 28 | Abstract 4523: Stool proteomics reveals new candidate biomarkers for colorectal cancer screening. <i>Cancer Research</i> , 2012, 72, 4523-4523. | 0.9 | 5 |
| 29 | CD31-positive microvessel density within adenomas of Lynch Syndrome patients is similar compared to adenomas of non-Lynch patients. <i>Endoscopy International Open</i> , 2019, 07, E701-E707. | 1.8 | 3 |
| 30 | Lipopolysaccharide-regulated secretion of soluble and vesicle-based proteins from a panel of colorectal cancer cell lines. <i>Proteomics - Clinical Applications</i> , 2021, 15, 1900119. | 1.6 | 2 |
| 31 | Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 563-571. | 1.4 | 0 |
| 32 | Abstract 4627: Proximal fluid proteome profiling of human colorectal cancer tissue reveals candidate biomarkers for CRC screening. , 2010, , . | | 0 |
| 33 | Abstract 3042: TPX2 and AURKA promote 20q amplicon driven colorectal adenoma-to-carcinoma progression. , 2011, , . | | 0 |
| 34 | Abstract 4526: Lumican and Versican predict good outcome in stage II and III colon cancer. , 2012, , . | | 0 |
| 35 | Abstract 109:CSE1L, a 20q gain passenger that drives colorectal adenoma to carcinoma progression. , 2012, , . | | 0 |
| 36 | Abstract 1563: Stool proteomics reveals novel candidate biomarkers for colorectal cancer screening. , 2015, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|----|-----------|
| 37 | Abstract 3885: Peptide-mediated "miniprep"™ isolation of extracellular vesicles for high-throughput proteomics; method evaluation and application in colon cancer. , 2016, , . | | 0 |
| 38 | Abstract 3176: Improved colorectal cancer screening by new stool-based protein markers. , 2016, , . | | 0 |
| 39 | Abstract A04: Chromosomal aberrations implicated in colorectal adenoma to carcinoma progression as markers of high-risk colorectal adenomas. , 2017, , . | | 0 |
| 40 | Abstract 1559: Proteogenomic analysis of alternative splicing in colorectal adenoma-to-carcinoma progression. , 2017, , . | | 0 |
| 41 | Abstract 2208: Peptide-mediated 'miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomics; method evaluation and application in colon cancer. , 2017, , . | | 0 |